NASDAQ:CAI Caris Life Sciences (CAI) Stock Price, News & Analysis $30.24 +0.71 (+2.39%) As of 02:30 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Caris Life Sciences Stock (NASDAQ:CAI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Caris Life Sciences alerts:Sign Up Key Stats Today's Range$29.02▼$31.5350-Day Range$16.45▼$32.2752-Week Range$14.19▼$33.65Volume2.36 million shsAverage Volume3.42 million shsMarket Capitalization$8.54 billionP/E Ratio84.39Dividend YieldN/APrice Target$27.36Consensus RatingModerate Buy Company Overview Caris Life Sciences is a biotechnology company focused on precision oncology and the use of molecular and artificial intelligence technologies to support cancer diagnosis and treatment decisions. The company analyzes tumor and blood samples to identify genetic, molecular and other biological characteristics that may help physicians select targeted therapies and develop individualized treatment plans. Its offerings include comprehensive tumor profiling, molecular testing and data-driven clinical support for oncologists and other healthcare providers. Caris also provides molecular data, research services and related technology to biopharmaceutical companies and academic researchers working on drug discovery, clinical development and biomarker research. Founded in 2008 and headquartered in Irving, Texas, Caris serves healthcare providers, patients, biopharmaceutical companies and research organizations, primarily in the United States and through international collaborations. The company was founded by David D. Halbert, who serves as its chairman and chief executive officer. Caris Life Sciences trades on the Nasdaq under the symbol CAI.AI Generated. May Contain Errors. Read More Caris Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreCAI MarketRank™: 2.4888422158 of 5 starsCaris Life Sciences scored higher than 50% of companies evaluated by MarketBeat, and ranked 553rd out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingCaris Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 8 buy ratings, 5 hold ratings, and 1 sell rating.Downside RiskCaris Life Sciences has a consensus price target of $27.36, representing about 9.9% downside from its current price of $30.37.Amount of Analyst CoverageCaris Life Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Caris Life Sciences' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth230.77% Earnings GrowthEarnings for Caris Life Sciences are expected to grow by 230.77% in the coming year, from $0.13 to $0.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Caris Life Sciences is 84.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Caris Life Sciences is 84.25, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.40.Price to Book Value per Share RatioCaris Life Sciences has a P/B Ratio of 14.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.83% of the float of Caris Life Sciences has been sold short.Short Interest Ratio / Days to CoverCaris Life Sciences has a short interest ratio ("days to cover") of 2.48, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Caris Life Sciences has recently increased by 4.20%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldCaris Life Sciences does not currently pay a dividend.Dividend GrowthCaris Life Sciences does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Caris Life Sciences is 333.33%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on EPS estimates, Caris Life Sciences will have a dividend payout ratio of 279.07% in the coming year. This indicates that Caris Life Sciences may not be able to sustain their current dividend.Read more about Caris Life Sciences' dividend. News and Social Media3.0 / 5News Sentiment0.79 News SentimentCaris Life Sciences has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Caris Life Sciences this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for CAI on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows2 people have added Caris Life Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Caris Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,205,419.00 in company stock.Percentage Held by Insiders50.00% of the stock of Caris Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsCaris Life Sciences has minimal institutional ownership at this time.Read more about Caris Life Sciences' insider trading history. Receive CAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caris Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAI Stock News HeadlinesCaris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026October 14 at 8:30 AM | prnewswire.comBofA Securities Adjusts Caris Life Sciences Price Target to $35 From $23October 9, 2026 | marketscreener.comMFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 14 at 1:00 AM | Weiss Ratings (Ad)Consensus price target for Caris Life Sciences decreased by 13.14% to MX$311.55October 6, 2026 | msn.comCaris Life Sciences, Inc. (CAI)October 6, 2026 | finance.yahoo.comIPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two MonthsOctober 2, 2026 | investors.comCaris Life Sciences (NASDAQ:CAI) Insider Sells $238,650.00 in StockSeptember 24, 2026 | insidertrades.comCaris Life Sciences (NASDAQ:CAI) Insider Brian Brille Sells 400,000 SharesSeptember 18, 2026 | insidertrades.comSee More Headlines CAI Stock Analysis - Frequently Asked Questions How have CAI shares performed this year? Caris Life Sciences' stock was trading at $26.98 at the start of the year. Since then, CAI shares have increased by 12.6% and is now trading at $30.3730. How were Caris Life Sciences' earnings last quarter? Caris Life Sciences, Inc. (NASDAQ:CAI) posted its quarterly earnings data on Thursday, February, 26th. The company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.27. The business's quarterly revenue was up 125.4% on a year-over-year basis. Read the conference call transcript. Is Caris Life Sciences doing a stock buyback? Caris Life Sciences' board authorized a share repurchase program on Monday, June 8th 2026, which allows the company to buy back $100,000,000 in shares, according to EventVestor. This means that the company could purchase up to 2.2% of its shares through open market purchases. Shares buyback programs are often a sign that the company's leadership believes its shares are undervalued. When did Caris Life Sciences IPO? Caris Life Sciences (CAI) raised $459 million in an IPO on Wednesday, June 18th 2025. The company issued 23,529,412 shares at a price of $19.00-$20.00 per share. Who are Caris Life Sciences' major shareholders? Caris Life Sciences' top institutional shareholders include Zevenbergen Capital Investments LLC (0.25%), Krilogy Financial LLC (0.01%), City Center Advisors LLC (0.01%) and NorthCrest Asset Manangement LLC (0.01%). Insiders that own company stock include David Baxley Spetzler, Jon Halbert, Brian J Brille, John Russel Denton, Luke Thomas Power and Jeff L Vacirca. View institutional ownership trends. How do I buy shares of Caris Life Sciences? Shares of CAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/26/2026Today10/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CAI's financial health is in the Green zone, according to TradeSmith. CAI has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:CAI CIK2019410 Webwww.carislifesciences.com Phone(866) 771-8946FaxN/AEmployees1,846Year Founded2008Price Target and Rating Average Price Target for Caris Life Sciences$27.36 High Price Target$36.00 Low Price Target$21.00 Potential Upside/Downside-9.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)$0.36 Trailing P/E Ratio84.39 Forward P/E Ratio232.84 P/E GrowthN/ANet Income-$68.09 million Net Margins10.62% Pretax Margin10.61% Return on Equity18.77% Return on Assets9.34% Debt Debt-to-Equity Ratio0.66 Current Ratio5.53 Quick Ratio4.88 Sales & Book Value Annual Sales$348.89 million Price / Sales24.52 Cash Flow$1.63 per share Price / Cash Flow18.62 Book Value$2.05 per share Price / Book14.77Miscellaneous Outstanding Shares282,595,000Free Float141,298,000Market Cap$8.55 billion OptionableN/A Beta0.86 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CAI) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredElon will prove them wrong againElon Musk's critics said self-driving cars were a pipe dream. Today, Tesla robotaxis carry passengers with no ...Paradigm Press | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caris Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caris Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
